What Do Analysts Predict for SWAV?

ShockWave Medical stock is trading -17.79% below its average target price of $284.89 after marking a 5.2% during today's evening session. Analysts are giving the mid-cap Medical Instruments & Supplies company an average rating of buy and target prices ranging from $165.0 to $330.0 per share.

The stock has an average amount of shares sold short at 3.9%, and a short ratio of 1.94. Since 1.18% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 93.3% of ShockWave Medical's shares being owned by this investor type.

Institutions Invested in ShockWave Medical

Date Reported Holder Percentage Shares Value
2023-06-30 Blackrock Inc. 10% 3,636,444 $851,727,918
2023-06-30 Vanguard Group Inc 10% 3,603,014 $843,897,943
2023-06-30 FMR, LLC 7% 2,434,974 $570,319,613
2023-06-30 Wellington Management Group, LLP 4% 1,352,723 $316,834,782
2023-06-30 Artisan Partners Limited Partnership 3% 1,147,784 $268,833,969
2023-06-30 Price (T.Rowe) Associates Inc 3% 1,091,050 $255,545,732
2023-06-30 State Street Corporation 3% 1,018,186 $238,479,526
2023-06-30 JP Morgan Chase & Company 2% 835,138 $195,606,023
2023-06-30 Invesco Ltd. 2% 773,776 $181,233,815
2023-06-30 Capital World Investors 2% 585,000 $137,018,700

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on ShockWave Medical.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.